Background: Atrial fibrillation (AF) is a common complication of acute myocardial infarction (AMI).The CHA₂DS₂VASc and CHADS₂risk scores are used to identify patients with AF at risk for stroke and to guide oral anticoagulants (OAC) use, including patients with AMI. However, the epidemiology of AF, further stratified according to patients' risk of stroke, has not been well characterized among those hospitalized for AMI.
Introduction
Atrial fibrillation (AF) is a cardiac arrhythmia that affects thousands of hospitalized Americans, with an increasing prevalence in the United States [1] , [2] . Atrial fibrillation is frequently observed as a complication of acute myocardial infarction (AMI), affecting 5-13% of all patients suffering an AMI [3] - [7] . New-onset and prevalent AF is not only associated with higher rates of in-hospital complications such as heart failure, stroke, and death [7] - [10] , but also a higher likelihood of re-hospitalization among hospital survivors of an AMI [7] .
The CHADS 2 and CHA 2 DS 2 VASc scoring systems are used to stratify patients with AF at risk for developing stroke and identify patients who may benefit from oral anticoagulation (OAC), including patients with AMI [8] , [11] , [12] .Although antiplatelet drugs prevent thromboembolic complications in patients with AMI, particularly those receiving percutaneous interventions (PCI), these agents have minimal impact on stroke risk in patients with AF [11] .
Therefore,prescription of OAC in addition to antiplatelet therapy is recommended for AMI patients with AF consistently in the ESC and ACC/AHA/HRS guidelines [11] , [13] .However, practice patterns vary widely, particularly when dual antiplatelet therapy is prescribed among AMI patients,largely due to concerns about the bleeding risk from "triple therapy", but also because many providers view newonset AF following AMI as being associated with lower risk for stroke [14] . Observational studies have lent credibility to these concerns by showing an elevated bleeding risk among patients treated with dual antiplatelet agents and OAC [15] .
Few investigations have described the epidemiology of AF among patients with AMI, further stratified according to stroke risk, or trends in OAC prescription and post-discharge complications among guideline-eligible AF patients with AMI. Therefore, we analyzed data from the multi-hospital, population-based, Worcester Heart Attack Study (WHAS) [7] , [8] , [16] , [17] .
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Methods
The WHAS is an ongoing, population-based, observational study of patients hospitalized at all 11 medical centers in central Massachusetts, documenting long-term trends in the incidence, morbidity, mortality, and complications of AMI [7] , [8] , [1] , [17] . Our analyses focused on patients who were hospitalized with a discharge diagnosis of AMI at all Worcester Standard Metropolitan Statistical Area (SMSA) hospitals during 8 biennial years between 1997 and 2011. We selected these study years based on the availability of data on AF status, CHADS 2 and CHA 2 DS 2 VASc scores, and systematic collection of OAC prescription rates and post-discharge outcomes.
Since this study primarily focused on post-discharge outcomes and OAC prescription, patients who died during hospitalization were excluded. Medical records of patients admitted for possible AMI at all metropolitan Worcester medical centers were reviewed and validated. Diagnosis of AMI was confirmed using pre-established criteria [18] . The methods used for the identification of patients hospitalized Original Research respiratory rate, serum creatinine and peak troponin), in-hospital and discharge medications, in-hospital complications and postdischarge outcomes. Rates of warfarin, aspirin, and clopidogrel prescription were determined based on the discharge medication list. Rates of direct oral anticoagulant prescription were not examined in this study, as these agents were not approved for use in the US until 2010, nor collected in this study until after 2011. Rigorous methods have been used to identify deaths and cases of read mission to area hospitals [7] . Patient's AF status was determined based on available clinical data [7] , [16] . A review of ambulance transport records, emergency admission notes, progress notes, and in-hospital 12-lead ECGs was conducted to identify patients with AF. The classification of prevalent AF was assigned if a patient had prior AF noted in their hospital admission note or any progress note. A case of incident, or newly diagnosed, AF was defined according to the following criteria: No documentation of pre-existing AF anda) AF on any 12-lead ECG obtained during the index hospitalization [8] , [17] , or b) new-onset AF documented in any clinical note during the index hospitalization. For purposes of focusing on post-discharge outcomes and discharge prescription practices, we included hospital survivors with both incident and prevalent AF. Patients who under went coronary artery bypass grafting (CABG) during hospitalizationwere excluded from the study due to the different mechanisms and natural historyof surgical patients with AF [19] .
Patients with confirmed AMI were further stratified according to their CHA 2 DS 2 VAScscore based on documentation of risk factors in the medical record [age, sex, history of heart failure, hypertension, diabetes mellitus, stroke or transient ischemic attack, vascular disease (including myocardial infarction and peripheral artery disease)]
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No AF AF- with AMI and various comorbidities and complications have been described in prior publications [7] , [8] , [16] , [17] . The data collected included patients' age, gender, race, comorbidities (hypertension, heart failure, stroke, hyperlipidemia, chronic obstructive pulmonary disease [COPD], chronic kidney disease [CKD], diabetes), type of AMI,physiologic parameters (admission heart rate, blood pressure, Table 5 :
Yearly Trends in Discharge Anticoagulation Prescription (%) in Patients with Acute Myocardial Infarction (AMI) and Atrial Fibrillation (AF), further stratified by CHA₂DS₂VASc scores [11] , [13] . Patients were grouped into 3 categories according to their CHA₂DS₂VASc score (Group 1 =CHA₂DS₂VASc score 1-2, Group 2 = CHA₂DS₂VASc 3-6, Group 3 = CHA₂DS₂VASc 7-9) to distinguish between those at lower, high, and very high risk of thromboembolism [20] [21] [22] [23] . Although use of the CHA₂DS₂VASc stroke risk score was introduced in 2009, the CHADS₂ scoring system was in use for most of the period under study. Therefore, we also stratified stroke risk category were more likely to have new-onset AF compared to prevalent AF, whereas patients with AF in the highest stroke risk group were older, more likely to be male, have higher serum troponin levels, have a history of CKD, and have higher average HAS-BLED scores. Patients with AF and higher CHA 2 DS 2 VASc scores were also more likely to have their AMI hospitalization complicated by development of heart failure or stroke. We also observed that in patients with AMI and AF, bleeding risk (based on HAS-BLED score) tracked closely with stroke risk [ Table 1 ].
Rates of AF increased significantly between 1997 and 2003, after which time AF rates remained relatively stable, and patterns did not appear to differ significantly according to CHA 2 DS 2 VASc stroke risk category[ Figure 1 ]. Rates were highest among patients with AF in the highest stroke risk group, but the relative proportion of individuals in the lowest stroke risk category appeared to increase during the most recent study years. Similar results were seen in AF rates stratified by CHADS 2 scores, with higher rates observed among patients with AF and a CHADS 2 score≥2 [ Figure 2 ].
In comparison to AMI patients who remained free from AF during their hospitalization, individuals with AF in the highest stroke risk category had significantly higher rates of post-discharge complications, including higher 30-day re-hospitalization rates [27 % vs. 17 %], 30-day post-discharge death rates [10 % vs. 5%], and 1-year post-discharge death rates [46 % vs. 18%] (p<0.001 for all). Notably, we observed a direct relationship between CHA 2 DS 2 VASc category and rates of readmission or death within 30 days, as well as death rates at 1-year [ Table 2 ]. Furthermore, after adjustment for several demographic factors, comorbid conditions, and AMIassociated characteristics, AF patients in the highest stroke risk group had 2-fold higher odds of dying at 1-year after discharge, compared to patients free from AF. However, adjustment for the same set of key covariates attenuated crude associations observed between stroke risk and readmission, as well as mortality 30-days after discharge [ Table  2 ].
We also examined the use of evidence-based medications for AMI or AF at discharge, further stratified by stroke risk. Rates of OAC use were highest among patients with highest CHA 2 DS 2 VASc scores (38% in the very high stroke risk, 35% in the high stroke risk, and 31% in the lowest stroke risk), but less than half of patients at high or very-high stroke risk received an OAC prescription at discharge. the cohort according to CHADS₂score (congestive heart failure, hypertension, age, diabetes, and stroke)using similar methods,but divided the population into two groups -those with CHADS₂ score less than two and those with a CHADS₂ score of two or more, in order to identify the proportion of the population eligible for OAC prescription based on contemporary guidelines [11] , [13] .
We examined differences in the frequency and outcomes of patients with AF compared to those without AF through the use of chisquare tests and one-way analysis of variance (ANOVA) for discrete and continuous variables, respectively. We examined differences in the characteristics and use of different evidence-based AMI and AF therapies according to stroke risk classifications through the Cochran-Armitage test for trends. Differences in post-discharge complications, including hospital re-admission and mortality, as well as the associated crude and multivariable adjusted odds ratios (OR) with 95% confidence intervals (CI), were assessed. The odds of developing these complications were adjusted for confounding demographic and clinical factors.
We restricted our analyses on post-discharge prescription rates of OAC to the study years 2003-2011 because data on OAC was not collected in this study until 2003. HAS-BLED scores were calculated to characterize participant's risk of bleeding on OAC using the following factors documented in the medical recordage, hypertension, abnormal renal/liver function, stroke, bleeding history, drugs or alcohol use (1 pointeach) [11] , [21] . Since INRs prior to admission were not abstracted as part of this population-based study, we were not able to determine time in therapeutic range over the preceding 4 weeks among individuals treated with vitamin K antagonists. Hospital re-admission data was collected at only 3 of the major Worcester hospitals, and was reported for the years 1999-2011. All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
Results
The baseline characteristics of 6,627 patients discharged from all participating medical centers in central Massachusetts with an independently confirmed AMI during the years under study are shown in [ Table 1 ]. The mean age of this population sample was 69 years, 40% were women, and approximately two-thirds presented with an initial AMI. A total of 1,050patients (16%) had AF. Of these, the majority were at a high (76 %) or very high risk (15 %) for stroke according to their CHA 2 DS 2 VASc score. Patients in the "lower" Original Research AMI and AF had a high or very high risk for thromboembolism based on having a CHA₂DS₂VASc score>2. However, only 1 out of 4 AMI patients with AF received dual antiplatelet therapy at the time of hospital discharge and less than half received OAC at discharge, suggesting thata treatment gap between guideline and real-world rates of prescription exists.
Reasons for the low rates of OAC usage among AMI patients with AF at hospital discharge may include lack of awareness of guidelines, provider or patient concerns over risk for bleeding with the use of OAC and antiplatelet drugs, or under-estimation of stroke risk from AF complicating AMI. Since the FDA approved the first target specific OAC agent, dabigatran, for use in 2010 and our study ended in 2011, we do not believe that the low rates of OAC seen in our study relate to the use of vitamin-K antagonist alternatives. Furthermore, we have generally observed high rates of adherence to AMI-specific guideline recommendations for effective patient management in this community-wide study, with the majority of eligible patients having been treated with aspirin, statins, beta-blockers and prompt percutaneous revascularization for STEMI [31] . This was corroborated in our analysis as the vast majority of AMI patients with AF received guideline-directed antiplatelet, lipid-lowering agents, and betablocker therapies [ Table 3 ]. Therefore, we do not believe that the low rate of observed OAC prescription reflects a general disregard among providers at participating hospitals for guideline recommendations. An alternative explanation for our findings is that, despite evidence to the contrary (7) , hospital providers may consider AF complicating an AMIto be of lesser clinical significance than AF in the community, irrespective of their CHADS₂ or CHA₂DS₂VASc scores.
Neither treatment nor outcomes of A Fare mandated publically reported quality metrics.It has not been until recently that the American Heart Association created and distributed a 'Get with the Guidelines' for AF, a mechanism to enhance adherence to guidelinerecommendations for AF treatment, including use of OAC for patients at intermediate and high stroke risk [32] . It is certainly possible that clinicians managing patients with AMI during the period under study may not have been aware of the importance of stroke risk estimation and OAC prescription for at-risk patients. It is our hope that, through increased public and clinician AF awareness, adherence to guideline recommendations for OAC among eligible AMI patients with AF will increase.
Strengths of the present study include the population-based design involving all patients hospitalized with AMI across central Massachusetts. Inclusion of all regional hospitals in Worcester, the large number of patients hospitalized with AMI and AF, and the use of standardized criteria for diagnosing AMI and AF were additional strengths. We were also able to control for a variety of potential confounding variables outside of the CHA₂DS₂VASc scoring system that could have contributed to post-discharge outcomes.
Limitations
Limitations of this study include the lack of data on type of AF (paroxysmal, persistent, or permanent) and the inability to determine the time in therapeutic INR range among patients with AF prior to admission. Our study population likely included a number of patients at high risk for bleeding, and we did not systematically assess Interestingly, aspirin and clopidogrel use were also lower among AMI patients with AF at highest stroke risk,compared to those at lower risk (88.5 % and 58.3% among those with AF in the lowest stroke risk category vs. 78.2 % and 33.9% among those with AF highest stroke risk, respectively). In contrast, prescription of beta-blockers and lipid-lowering agents did not vary among AF patients based on stroke risk [Table 3 ].
Notably, only 1 in 4 AMI patients with AF and a high or very high stroke risk score received dual antiplatelet therapy at hospital discharge. Low rates of OAC prescription at discharge were also observed when stratifying the patients based on their CHADS 2 score[ Table 4 ]. We did not observe any significant change in the rates of OAC prescription over time among individuals with AF [ Table 5 ]. Lastly, in AF patients at elevated stroke risk, we observed no significant relations between bleeding risk and rates of OAC prescription at discharge [ Table 6 ].
Discussion
The CHA₂DS₂VASc scoring system is a well-validated stroke risk stratification tool for patients with non-valvular AF [24] . Components of the CHA₂DS₂VASc score are readily available prognostic risk factors for outcomes of is chemic heart disease [25] . The CHA₂DS₂VASc score has been shown to successfully estimate the risk of adverse events in patients with AMI [24] and also identify post-STEMI patients at high risk of developing new onset AF and stroke [26] .
There are limited studies that have evaluated the prognostic utility of stroke risk classification schemes in predicting the risk of adverse outcomes in patients with concomitant AMI and AF.In a study of more than 15,000 patients admitted with AMI to hospitals in Korea, the investigators assessed the utility of CHA₂DS₂VASc scores in predicting the risk of dying and/or recurrent MI in patients with and without AF. They found that higher CHA₂DS₂VASc scores were associated with an increased risk of adverse cardiovascular outcomes in AMI patients at 1,6,12, and 24 months, irrespective of the presence of AF [27] . In our community-wide study involving almost 7,000 hospital survivors, patients with AF and a higher CHA₂DS₂VASc scores were at greater risk for both short-and long-term adverse events than both AF patients with lower CHA₂DS₂VASc scores, and patients without AF. In particular, we observed a direct relationship between increasing CHA₂DS₂VASc scores and odds of dying at 1-year after discharge in patients with AF, compared to patients free from AF. This was not seen in AF patients with a low CHA₂DS₂VASc score [ Figure 3 ]. Our findings expand on the results of the previous Korean study (27) , and suggest that the CHA₂DS₂VASc system can be used as a tool to predict survival among patients with AMI and AF.
Current AF and AMI management guidelines support the use of dual antiplatelet therapy plus OAC when independent indications for AMI and AF exist [28] , [29] . However, institution of "triple therapy" poses risks for bleeding. Inasmuch, alternative strategies have been proposed for patients with AMI and AF, such as discontinuing antiplatelet drugs among patients who are greater than 12 months out from undergoing a PCI [30] . In clinical practice, there is significant individualization of treatment with respect to balancing the risks of stroke and bleeding.In our study, approximately 90% of patients with components of frailty, such as falls, weight loss, or grip strength, which may influence decisions to with hold OAC. We also did not assess for patient-level factors, such as patient's attitudes about OAC, allergies or prior adverse reactions that may have led to the with holding of OAC's at the time of hospital discharge.Data on prescription rates of anti arrhythmic medications in patients with AF was not collected. Since this study was conducted in a single geographic region, there was potential for under-estimation of re-hospitalization rates, as patients may have presented outside of the hospital network for subsequent hospitalizations. Moreover, hospital re-admission data was reported at only 3 of the major Worcester hospitals, although these comprise the majority of all AMI admissions in this population. Data on the etiology of death after hospital discharge was not available.
Conclusions
We observed that a large proportion of patients hospitalized for AMI over a 14-year period had AF,and that the proportion of AF patients at high risk for stroke remained elevated throughout the study. Another interesting finding was that less than half the patients with a high CHA 2 DS 2 VASc were discharged on anticoagulation therapy. Our findings suggest significant deviation from guidelinebased AF management practices in the context of AMI, and that patients with higher CHA 2 DS 2 VASc scores may benefit from greater monitoring and/or more aggressive treatment in the peri-discharge period. Future studies are needed to see if the CHA 2 DS 2 VASc score can truly be validated as tool for not only predicting stroke risk, but also post-discharge outcomes (including mortality) in patients with AMI and AF.
